Regulatory

Quarterly Report Q1 2021: US office opened in preparation of launch

2021-05-12
Download
Presentation
Webcast

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q1 2021 (January – March 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations

SIGNIFICANT EVENTS IN Q1 2021

  • Presentation of the clinical development plan for Oncoral
  • Opening of US office in preparation for the planned launch of Mangoral
  • Directed new share issue of SEK 200 million

SIGNIFICANT EVENTS AFTER THE PERIOD

  • EGM approval of the directed new share issue
  • Issuance and repurchase of C-shares for share saving program

FINANCIAL SUMMARY Q1 2021

  • Operating result of SEK -33.7M (SEK -20.7M)
  • Earnings per share of SEK -1.00 (SEK -0.71)
  • Cash flow from operations of SEK -22.9M (SEK -18.4M)
  • Cash and marketable securities of SEK 165.4M (SEK 169.3M)

“The first quarter gave a strong start of the new year to Ascelia Pharma. We continued to make progress in the clinical development program and the commercial preparations for our Phase 3 diagnostic drug Mangoral, including opening our US office in preparation for the planned launch. We also completed a directed new share issue of SEK 200 million to accelerate Mangoral launch preparations and start the Phase 2 clinical study of our oral chemotherapy Oncoral.”, said Magnus Corfitzen, CEO of Ascelia Pharma.

A presentation for analysts, investors and media will be held today 12 May at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos, CMO Carl Bjartmar and CCO Julie Waras Brogren. The presentation will be held in English. The presentation can be followed live via the link: https://tv.streamfabriken.com/ascelia-pharma-q1-2021

It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website: https://www.ascelia.com/ir-media/reports-presentations/

To participate in the telephone conference, please use the dial-in details shown below:
SE: +46 850 558 369
UK: +44 333 3009 260
US: +1 833 2498 403
DK: +45 787 232 50

2021-09-21

Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®

Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF® (trifluri ...
2021-08-19

Quarterly Report Q2 2021: Preparing Oncoral for the next level

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2 2021 (April – June 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/
2021-08-18

Covid-19 extends recruitment period of SPARKLE study

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the continued global impact of the Covid-19 pandemic could extend the recruitment period of the clinical phase 3 study SPARKLE with up to 6 months. The recruitment is now expected to be completed during H1 2022. Ascelia Pharma has a solid cash position supporting operations well into 2023.